Prostate — In Follow-up

Enzalutamide is a new hormone treatment taken as tablets. Previous trials have proven that enzalutamide improves survival and quality of life in people with prostate cancer that has stopped responding to standard hormone treatments and chemotherapy.

This large, international randomised trial was undertaken to determine if treatment with enzalutamide can improve survival and quality of life in people starting hormone treatment for newly diagnosed prostate cancer that has spread beyond the prostate. The trial was led from Australia by ANZUP in collaboration with the NHMRC Clinical Trials Centre. It involved 1,125 people from Australia, New Zealand, Canada, the US, Ireland, and the UK.

In 2020 the ENZAMET trial won all three of the Australian Clinical Trials Alliance (ACTA) Awards. The ENZAMET trial was awarded the 2020 ACTA Trial of the Year Award, the ACTA STInG Award for Excellence in Trial Statistics and the Consumer Involvement Award.

This landmark Australian led clinical trial, ENZAMET, has now shown that hormone therapy with a drug called enzalutamide can improve the survival of some people with advanced, hormone-sensitive prostate cancer. Findings from the ENZAMET trial, led by ANZUP, have shown that people with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in survival compared to people receiving standard treatment alone and a 60% improvement in the time it takes to detect the cancer growing again. These results were much better than it was thought they might be when the trial began.

The ANZUP investigator initiated studies were financially supported by Astellas, who also provided enzalutamide.
If you think this trial might be right for you, please ask your doctor.
Trial Title
Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: a randomised phase III trial
Cancer Type
Trial Status
In Follow-up
Protocol Number
ANZUP 1304
Co-ordinating centre
Study Chair
Professor Ian Davis and Professor Christopher Sweeney
Patient Population
Men with metastatic prostate cancer commencing androgen deprivation therapy
Detailed Information
Further Information
Participating Centres
Central West Cancer Services
Chris O'Brien Lifehouse - Sydney Local Health District
Concord Repatriation General Hospital
Nepean Hospital
North Coast Cancer Institute, Coffs Harbour
GenesisCare Northern Cancer Institute St Leonard's
Mid North Coast Local Health District - Port Macquarie Base Hospital
Prince of Wales Hospital - South Eastern Sydney Health District
Riverina Cancer Care Centre
St George Hospital - South Eastern Sydney Local Health District (SESLHD)
St Vincent's Hospital - Sydney
Sydney Adventist Hospital
North West Cancer Centre -Tamworth Hospital
The Tweed Hospital
Wollongong Hospital
Border Medical Oncology Research Unit

Austin Hospital
Australian Urology Associates
Bendigo Hospital
Eastern Health
Geelong Hospital
Goulburn Valley Health
Monash Cancer Center - Moorabbin
Peninsula South Eastern Haematology & Oncology Group (PSEHOG)
Peter MacCallum Cancer Centre - East Melbourne
St Vincent's Hospital - Melbourne

Gold Coast Hospital
Nambour General Hospital
Princess Alexandra Hospital
Royal Brisbane & Women's Hospital
The Townsville Hospital

Royal Darwin Hospital

Ashford Cancer Centre Research
Flinders Medical Centre
Royal Adelaide Hospital - Central Adelaide Local Health Network Inc.

Royal Hobart Hospital

Fiona Stanley Hospital
Sir Charles Gairdner Hospital 

Auckland City Hospital
Christchurch Hospital
Waikato General Hospital

St James Hospital
Aberdeen Royal Infirmary
Royal Sussex Hospital
Great Western General Hospital
Guy's and St. Thomas Hospital
Kent & Canterbury Hospital
Royal Cornwall Hospital
Barts Health NHS Trust, Bartholomew's Hospital
The Royal Marsden Hospital
University Hospital Southampton
University College London Hospitals
Velindre Cancer Centre

Adelaide and Meath Hospital – National Children Hospital
Beacon Private Hospital Dublin
Beaumont Hospital
Galway University Hospital
Mater Misericordiae University Hospital
Mater Private Hospital
St Vincents University Hospital
University Hospital Waterford

Algoma District Cancer Program Sault Area Hospital
Allan Blair Cancer Centre
BC Cancer Agency (BCCA) Fraser Valley
BC Cancer Agency Vancouver Cancer Centre
Cambridge Memorial Hospital
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Cancer Care Manitoba
Hopital Notre-Dame
CHUQ-Pavillon Hotel-Dieu de Quebec
Cross Cancer Institute
Dr. Everett Chalmers Hospital - Horizon Health Network
Juravinski Cancer Centre
Lakeridge Health Oshawa
London Regional Cancer Program
Ottawa Hospital Cancer Centre
Princess Margaret Cancer Centre
QEII Health Sciences Centre CDHA
Saint John Regional Hospital
Saskatoon Cancer Centre
Southern Alberta Institute of Urology
Thunder Bay Regional Health Science Centre

Dana-Farber Cancer Institute

Participating Centres